ISB 1342-101

Drug Ichnos Sciences Inc.
Total Payments
$739,369
Transactions
65
Doctors
8
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $739,369 65 8

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $739,369 65 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
ISB 1342-101 Ichnos Sciences Inc. $739,369 8

Top Doctors Receiving Payments for ISB 1342-101

Doctor Specialty Location Total Records
, M.D Hematology & Oncology Nashville, TN $386,889 15
, M.D Medical Oncology Baltimore, MD $117,529 4
, M.D Hematology & Oncology Nashville, TN $65,515 20
, M.D Medical Oncology New York, NY $64,170 6
, MD, PHD Medical Oncology New York, NY $56,926 3
, MD Hematology & Oncology Denver, CO $36,333 14
, MD Hematology Hackensack, NJ $8,197 1
, MD Hematology & Oncology Little Rock, AR $3,810 2

About ISB 1342-101

ISB 1342-101 is a drug associated with $739,369 in payments to 8 healthcare providers, recorded across 65 transactions in the CMS Open Payments database. The primary manufacturer is Ichnos Sciences Inc..

Payment data is available from 2020 to 2020. In 2020, $739,369 was paid across 65 transactions to 8 doctors.

The most common payment nature for ISB 1342-101 is "Unspecified" ($739,369, 100.0% of total).

ISB 1342-101 is associated with 1 research study, including "ISB 1342-101" ($739,369).